Enveric Biosciences announced the issuance of two new patents from the US Patent and Trademark Office (USPTO) supporting its EVM301 and EVM201 series compounds.
These patents increase the total number of patents to 11 for the EVM301 series.
The new patents protect novel, non-obvious, multi-substituent and halogenated psilocybin derivative compounds and their pharmaceutical formulations containing such compounds, respectively.
Enveric Biosciences is a biotechnology company focused on developing neuroplastogenic, small-molecule therapeutics intended for the treatment of anxiety, depression, and addiction disorders.
The firm’s lead candidate, EB-003, is one of the compounds from its EVM301 series. This candidate was developed from its proprietary Psybrary molecular library, which includes over 1,000 tryptamine derivatives featuring receptor engagement and functional data that correlates structure with biological activity.
EB-003 is intended to target anxiety, depression, and addiction disorders.
According to Enveric Biosciences, recent pre-clinical data indicate EB-003’s potential to promote neuroplasticity and demonstrates that it can be orally administered at effective doses without causing hallucinations. These factors make EB-003 promising for both commercial and regulatory success.
Enveric Biosciences director and CEO Joseph Tucker said: “These patent issuances from the USPTO add important pillars to Enveric’s intellectual property portfolio as we continue to distinguish the pre-clinical performance of our tryptamine-based molecules under development for the treatment of mental health disorders from others on the market or under development.
“Importantly, with our focus squarely on our EVM301 Series, we expect to continue uncovering positive data highlighting the promising properties of EB-003, which is designed to capitalise on the potential for inducing neuroplasticity without causing hallucinations that can meet key commercial and regulatory criteria to advance to clinical trials.”
Additionally, the biotechnology company announced the issuance of two more US patents for its EVM201 series prodrug molecules.
These patents protect novel C4-carboxylic acid-substituted tryptamine derivatives compounds and their related pharmaceutical formulations. These molecules are specifically designed to address neurological disorders.
Enveric Biosciences recently licensed its EVM201 Series to MycoMedica Life Sciences, which plans to develop the lead compound, EB-002. These patents further enhance the value of the collaboration between the two companies.
Furthermore, the psilocybin derivatives developer has also signed out-licensing deals with Aries Science & Technology to focus its resources on the development of its lead compound EB-003.
Enveric Biosciences is headquartered in Naples, Florida, with offices in Cambridge, and Calgary, Canada.
